92 related articles for article (PubMed ID: 26239718)
1. Ethnicity and prostate cancer: the way to solve the screening problem?
Bokhorst LP; Roobol MJ
BMC Med; 2015 Aug; 13():179. PubMed ID: 26239718
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-Term Risk of Prostate Cancer is Directly Related to Baseline Prostate Specific Antigen: Implications for Reducing the Burden of Prostate Specific Antigen Screening.
Gelfond J; Choate K; Ankerst DP; Hernandez J; Leach RJ; Thompson IM
J Urol; 2015 Jul; 194(1):46-51. PubMed ID: 25686543
[TBL] [Abstract][Full Text] [Related]
3. [Advancements in PSA-based screening for prostate cancer].
Ito K
Rinsho Byori; 2004 Jul; 52(7):611-7. PubMed ID: 15344561
[TBL] [Abstract][Full Text] [Related]
4. Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study.
Carlsson S; Assel M; Ulmert D; Gerdtsson A; Hugosson J; Vickers A; Lilja H
Eur Urol; 2017 Jan; 71(1):46-52. PubMed ID: 27084245
[TBL] [Abstract][Full Text] [Related]
5. Early detection of prostate cancer. What do we tell our patients?
Schröder FH; Erasmus MC
Can J Urol; 2006 Apr; 13 Suppl 2():37-42. PubMed ID: 16672127
[TBL] [Abstract][Full Text] [Related]
6. Lifetime risk of being diagnosed with, or dying from, prostate cancer by major ethnic group in England 2008-2010.
Lloyd T; Hounsome L; Mehay A; Mee S; Verne J; Cooper A
BMC Med; 2015 Jul; 13():171. PubMed ID: 26224061
[TBL] [Abstract][Full Text] [Related]
7. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians.
Qaseem A; Barry MJ; Denberg TD; Owens DK; Shekelle P;
Ann Intern Med; 2013 May; 158(10):761-769. PubMed ID: 23567643
[TBL] [Abstract][Full Text] [Related]
8. A framework for the identification of men at increased risk for prostate cancer.
Roobol MJ; Schröder FH; Crawford ED; Freedland SJ; Sartor AO; Fleshner N; Andriole GL
J Urol; 2009 Nov; 182(5):2112-20. PubMed ID: 19758625
[TBL] [Abstract][Full Text] [Related]
9. Screening for prostate cancer.
Brawley OW; Ankerst DP; Thompson IM
CA Cancer J Clin; 2009; 59(4):264-73. PubMed ID: 19564245
[TBL] [Abstract][Full Text] [Related]
10. [Prostate cancer screening].
Villers A; Rébillard X; Soulié M; Davin JL; Coloby P; Moreau JL; Mejean A; Irani J; Coulange C; Mangin P;
Prog Urol; 2003 Apr; 13(2):209-14. PubMed ID: 12765053
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer screening.
Roetzheim RG; Herold AH
Prim Care; 1992 Sep; 19(3):637-49. PubMed ID: 1384077
[TBL] [Abstract][Full Text] [Related]
12. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras.
Sun L; Caire AA; Robertson CN; George DJ; Polascik TJ; Maloney KE; Walther PJ; Stackhouse DA; Lack BD; Albala DM; Moul JW
J Urol; 2009 Nov; 182(5):2242-8. PubMed ID: 19758616
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer epidemiology.
Plata Bello A; Concepcion Masip T
Arch Esp Urol; 2014 Jun; 67(5):373-82. PubMed ID: 24914835
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific antigen-based screening for prostate cancer in the third millennium: useful or hype?
Lippi G; Montagnana M; Guidi GC; Plebani M
Ann Med; 2009; 41(7):480-9. PubMed ID: 19657768
[TBL] [Abstract][Full Text] [Related]
16. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Schröder FH
Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
[TBL] [Abstract][Full Text] [Related]
17. The Effect of Start and Stop Age at Screening on the Risk of Being Diagnosed with Prostate Cancer.
Godtman RA; Carlsson S; Holmberg E; Stranne J; Hugosson J
J Urol; 2016 May; 195(5):1390-1396. PubMed ID: 26678954
[TBL] [Abstract][Full Text] [Related]
18. Screening men for prostate cancer and colorectal cancer: is practice evidence-based?
Chun FK; Suardi N; Perrotte P; Lebeau T; Guay JP; Benayoun S; Ramirez A; Bénard F; McCormack M; Valiquette L; Karakiewicz P
Can J Urol; 2007 Dec; 14(6):3727-33. PubMed ID: 18163923
[TBL] [Abstract][Full Text] [Related]
19. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
[TBL] [Abstract][Full Text] [Related]
20. Benefits and harms of prostate cancer screening - predictions of the ONCOTYROL prostate cancer outcome and policy model.
Mühlberger N; Boskovic K; Krahn MD; Bremner KE; Oberaigner W; Klocker H; Horninger W; Sroczynski G; Siebert U
BMC Public Health; 2017 Jun; 17(1):596. PubMed ID: 28651567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]